Investment Basics

Gland Pharma Q1 2023 Concall Highlights

Price pressures and syringe shortage plus other supply chain issues (Impact of shortage of API and primary packing materials) witnessed in the US. Management expects the new launches to normalize the impact. Ensured timely new product launches and commercialized key products such as Bortezomib, Pemetrexed, Pantoprazole and Cyanocobalamin in the US market. Received 180 days …

Gland Pharma Q1 2023 Concall Highlights Read More »